Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novo Nordisk A/S (NYSE:NVO)

56.05
Delayed Data
As of May 26
 -0.25 / -0.44%
Today’s Change
46.17
Today|||52-Week Range
60.34
-3.50%
Year-to-Date
3 Stocks Underperforming Today In The Drugs Industry
May 26 / TheStreet.com - Paid Partner Content
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
May 24 / Zacks.com - Paid Partner Content
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
May 26 / Zacks.com - Paid Partner Content
Businesses That Win Trait No. 3: Long-Term Thinking
May 24 / MotleyFool.com - Paid Partner Content
Novo Nordisk IDegLira Recommended by FDA Advisory Committee
May 25 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close56.30
Today’s open55.93
Day’s range55.79 - 56.13
Volume2,034,549
Average volume (3 months)1,503,911
Market cap$110.4B
Dividend yield1.71%
Data as of 05/26/2016

Growth & Valuation

Earnings growth (last year)+12.05%
Earnings growth (this year)--
Earnings growth (next 5 years)+12.35%
Revenue growth (last year)+1.43%
P/E ratio4.2
Price/Sales9.38
Price/Book20.98

Competitors

 Today’s
change
Today’s
% change
SNYSanofi+0.14+0.34%
GSKGlaxoSmithKline-0.03-0.07%
BMYBristol-Myers Squibb+0.04+0.06%
ABBVAbbVie+0.68+1.11%
Data as of 05/26/2016

Financials

Next reporting dateAugust 5, 2016
EPS forecast (this quarter)$0.59
Annual revenue (last year)$16.0B
Annual profit (last year)$5.2B
Net profit margin32.30%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
President &
Chief Executive Officer
Lars Rebien Sørensen
Chief Financial Officer &
Executive Vice President
Jesper Brandgaard
Corporate headquarters
Bagsværd, Capital Region

Forecasts

Partner Offers

Search for Jobs